Replies to post #331857 on Avid Bioservices Inc (CDMO)

[4OurRetirement]

Here's English Translation Of Oncologie & Bavituximab Article...

From The Interesting Link jakedogman1 supplied:
https://dinghangyiyao.cn/xwg/info.aspx?itemid=94

*****************************************************

Quote:

"Dinghang Pharmaceutical announced the clinical data of Bavituximab in
the 2019 CSCO annual meeting
2019-09-19
Shanghai and Boston, September 19, 2019 - Oncologie, the global leader in tumor
immunotherapy, is here todayThe 22nd China Society of Clinical Oncology Annual Meeting
(CSCO2019 Annual Meeting) unveiled a study summary of its innovative drug
Bavituximab, an Asian and non-Asian advanced non-small cell lung cancer that
participated in a previous phase III lung cancer clinical trial. The plasma concentrations of
Bavituximab in patients (NSCLC) were analyzed and compared.
Studies have shown that the blood levels of Bavituximab in Asian and non-Asian patients
are very similar, and overall safety is consistent across different populations. More
NEWS
NEWS CENTER
COMPANY
company news
EN
research data and details will be presented in the form of a wall report at the 2019CSCO
Annual Meeting in Xiamen from September 18th to September 22nd.
“I am very pleased that Dinghang Pharmaceutical will be able to participate in the CSCO
Annual Meeting for the first time this year and have in-depth exchanges with experts and
scholars in the industry,” said Dr. Laura Benjamin, co-founder and CEO of Dinghang
Pharmaceutical. “Based on the results of this announcement, we More people in Asia will
be enrolled in the Bavituximab clinical study in the world. Dinghang Medicine is actively
communicating with the health departments of Asian countries, hoping to carry out
Bavituximab's multiple refractory problems in China and more Asian countries as soon as
possible. Clinical research on cancer."
About Bavituximab
Bavituximab is a clinical stage of innovative chimeric monoclonal antibody drugs targeting
phosphatidylserine (PS). Bavituximab is thought to reverse PS-mediated
immunosuppression by blocking the binding of PS to its receptor. Studies have shown that
antibodies targeting PS have the function of activating immune cells in tumors, and can
trigger various reactions such as human immune activation and anti-tumor immune
response. By reversing the mechanism of immunosuppression, PS antibodies will likely
help other cancer therapies attack tumors more efficiently and without restriction. It is
worth mentioning that Bavituximab exhibits a well-controlled safety and tolerability in
several clinical trials conducted to date, which will allow it to be effectively combined with
other therapies. Bavituximab has not been approved for sale in any country.
About Dinghang Medicine
Founded in 2018, Dinghang Pharmaceutical is committed to the discovery and
development of new drugs for combination therapy for tumor immunity, based in Boston,
USA and Shanghai, China. With the academic expertise and extensive business
experience of the founding team, the company has established a group of new drug
candidates with global intellectual property that are highly differentiated. The company's
product candidates include a new mechanism of First-in-class drugs and Best-in-class
drugs for improved and improved existing drugs, as well as a companion diagnostic
platform for tumor immunotherapy, two of which have entered the clinical stage. The
company is currently conducting three clinical trials simultaneously. Dinghang
Pharmaceutical is willing to work with global partners to develop the next generation of
cancer products for the benefit of more cancer patients.
© 2019 Shanghai Ding Hang Biological Technology Co., Ltd. Designed by Wanhu"